Your SlideShare is downloading. ×
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

**Wright - Clinical Practice Guidelines Evolution at the American College of Cardiology

434

Published on

Published in: Health & Medicine, Education
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
434
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. CPGS: Evolution at ACCConsumers United for Evidence-based Healthcare 2011 Annual Membership Meeting August 12, 2011 Washington, DC Janet Wright MD FACC Sr VP for Science and Quality American College of Cardiology
  • 2. Disclosures• Financial• Professional/Personal – ACC – Consumer influence on healthcare – Speaker underperformance • jwright@acc.org
  • 3. Standards for Developing Trustworthy Clinical Practice Guidelines Establish Transparency Manage Conflict of Interest Create Multidisciplinary Guideline Development Group Composition Perform Systematic Evidence Review Establish Evidence Foundations for Rating Strength of Recommendations Articulate Recommendations Establish External Review Update IOM Report , March 2011 http://www.nap.edu/catalog/13058.html
  • 4. Potential Impact of IOM Standards on ACC/AHA Guideline Development• Standard 1: Establish Transparency  Neither ACC nor AHA accept funding for Clinical Practice Guidelines  All ACC and AHA funding sources are publicly accessible on our websites
  • 5. Potential Impact of IOM Standards on ACC/AHA Guideline Development• Standard 2: Manage Conflict of Interest Relationship with Industry (RWI) Define Disclose Manage
  • 6. Define: When it is Relevant For the purpose of identifying who can be appointed as a chair and/or member of a writing committee, a person has a relevant relationship with a company or other entity IF:• The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or• The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or• The person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
  • 7. Disclose• In Advance – RWI reviewed and vetted to ensure balanced committee• Ongoing – verbal and in writing at every meeting and conference call• Published – in print and online using a tabular format to highlight type and level of relationship; publication of all relevant relationships for authors and peer reviewers with each guideline, including documentation of sections from which authors recuse themselves from writing/voting, as well as online posting of author and oversight Task Force member comprehensive RWI
  • 8. Manage: The Writing and Voting ProcessIf a member of a writing committee has a relevant RWI regarding a product or competing product in the section of the document then the member is permitted to participate in the discussions but is not permitted to draft or vote on a recommendation and/or corresponding text.
  • 9. Manage: The Writing and Voting Process Chair plus 50% of writing committee may have no relevant RWI Potential WC members do not “self-filter” for relevant RWI Policy extends to 12 month period prior to invitation and includes products in development
  • 10. Potential Impact of IOM Standards on ACC/AHA Guideline Development Standard 3: Create Multidisciplinary Guideline Development Group Composition Harmonization is key - full partnership to all stakeholder organizations WCs are inclusive: methodologist, nurses, pharmacologist, internal medicine physicians Balance and diversity: gender, race, ethnicity, geographic location, practice vs. academic, low/high volume centers Patients and consumers not yet included on writing committees
  • 11. Potential Impact of IOM Standards on ACC/AHA Guideline Development Standard 3: Create Multidisciplinary Guideline Development Group Composition Patients and consumers not yet included on writing committees WHY NOT?  Unknown pool of folks trained in EBM  Burden and expense of that training  Delay in development of Guideline  Potential for introduction of bias contradictory to the evidence adjudication process (esp with LOE: C recommendations)
  • 12. Potential Impact of IOM Standards on ACC/AHA Guideline DevelopmentStandard 4: Perform Systematic Evidence Review √ Area of opportunity for ACC/AHA  Evidence review is implicit in our currently evolving process
  • 13. ACCF/AHA Guideline Development Methodology Guideline Literature Evidence Tables Recommendation Topic Review Analysis Development Ad Hoc-Mostly set Summaryand Recommendations Tables-preselected supported by Future currently-Cover references and sub-section beingbroad summary tables searches piloted indisease PICO PCI, STEM In Processbased questions Evidence I, andtopics Grading Tool CABG Summary Tables
  • 14. Potential Impact of IOM Standards on ACC/AHA Guideline DevelopmentStandard 5: Establish Evidence Foundations for Rating Strength of Recommendations  Area of opportunity for ACC/AHA  Strength of recommendation is ranked using a standardized classification (COR) based on the size of the treatment effect (benefit vs risk)  Level of evidence is ranked using a standardized classification (certainty of precision of treatment effect)  Validity and reliability of new tool to rate quality of evidence currently being tested
  • 15. Potential Impact of IOM Standards on ACC/AHA Guideline DevelopmentStandard 6: Articulate Recommendations  Our standard COR/LOE Table includes required verbs (standard phrases) linked to each COR  All recommendations are articulated in a standardized form detailing the recommended action and under what circumstances it should be performed  “Comparator verbs” added to the Table to allow for direct comparison of therapies  Language added denoting no benefit vs. harm of treatment for Class III recommendations
  • 16. Potential Impact of IOM Standards on ACC/AHA Guideline Development Standard 7: Establish External Review Rigorous review process that includes all relevant stakeholders and oversight bodies of ACC and AHA We do NOT open our review process for public comment. Concerns expressed include - potential for industry influence - inability to detect, track, and manage RWI - time delays and resources to review and process - compromise of publication embargos
  • 17. Potential Impact of IOM Standards on ACC/AHA Guideline DevelopmentStandard 8: Update CPG: New, Revised, Updated (Focused Update) Literature and major meetings are monitored Twice yearly Writing Committees evaluate the impact of new evidence on current recommendations. Guidelines are updated based on the evaluation of the Writing Committee and the Task Force. A major challenge is to create a “living guideline” where all updated recommendations are incorporated back into original guideline.

×